Search hospitals > Michigan > Port Huron
McLaren-Port Huron
Claim this profilePort Huron, Michigan 48060
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Colorectal Cancer
Conducts research for Prostate Cancer
48 reported clinical trials
11 medical researchers
Summary
McLaren-Port Huron is a medical facility located in Port Huron, Michigan. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Colorectal Cancer, Prostate Cancer and other specialties. McLaren-Port Huron is involved with conducting 48 clinical trials across 77 conditions. There are 11 research doctors associated with this hospital, such as Ammar Sukari, Anteneh A. Tesfaye, Anthony F. Shields, and Mohammed N. Al Hallak.Area of expertise
1Cancer
Global LeaderStage III
Stage IV
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Ammar SukariWayne State University/Karmanos Cancer Institute1 year of reported clinical research
Expert in Squamous Cell Carcinoma
Expert in Cancer
27 reported clinical trials
44 drugs studied
Anteneh A. TesfayeWayne State University/Karmanos Cancer Institute4 years of reported clinical research
Studies Colorectal Cancer
Studies Tumors
18 reported clinical trials
37 drugs studied
Anthony F. ShieldsBarbara Ann Karmanos Cancer Institute4 years of reported clinical research
Studies Solid Tumors
Studies Tumors
20 reported clinical trials
62 drugs studied
Mohammed N. Al HallakWayne State University/Karmanos Cancer Institute4 years of reported clinical research
Studies Pancreatic Cancer
Studies Colorectal Cancer
17 reported clinical trials
33 drugs studied
Clinical Trials running at McLaren-Port Huron
Gastric Cancer
Esophageal Cancer
Esophageal Adenocarcinoma
Breast Cancer
Lung Cancer
Prostate Cancer
Gastroesophageal Junction Adenocarcinoma
Anal Cancer
Cancer
Adenocarcinoma
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Chemotherapy + Radiotherapy
for Esophageal and Gastric Cancer
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at McLaren-Port Huron?
McLaren-Port Huron is a medical facility located in Port Huron, Michigan. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Colorectal Cancer, Prostate Cancer and other specialties. McLaren-Port Huron is involved with conducting 48 clinical trials across 77 conditions. There are 11 research doctors associated with this hospital, such as Ammar Sukari, Anteneh A. Tesfaye, Anthony F. Shields, and Mohammed N. Al Hallak.